Barclays analyst Geoff Meacham maintained a Sell rating on Prothena Corp (PRTA) on May 29 and set a price target of $9. The company’s shares opened today at $9.36, close to its 52-week low of $8.63.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 4.2% and a 53.9% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Kiniksa Pharmaceuticals Ltd.
Currently, the analyst consensus on Prothena Corp is a Hold with an average price target of $14.50.
See today’s analyst top recommended stocks >>
Based on Prothena Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $20.87 million. In comparison, last year the company had a GAAP net loss of $48.74 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease.
